| Literature DB >> 22936935 |
Robert B Ratts1, Nan-Ping Weng.
Abstract
Age-associated decline of immune function is believed to be mainly due to alterations of immune cells. However, longitudinal changes of human immune cells with age have not yet been adequately addressed. To test the hypothesis that regeneration of lymphocytes and monocytes is robust throughout most of adult life until advanced age, we examined six leukapheresis donors (3 young and 3 middle-aged/old) who donated approximately 10% of their peripheral blood mononuclear cells (PBMC) every other month over 3-5 years. We found the number of both lymphocytes and monocytes were quite stable in the blood of all six donors. As expected, young donors had more T cell receptor excision circles (TRECs), CD31{}(+) cells (CD4 only) and longer telomeres in T cells than did the middle-aged donors. Interestingly, more variation in TREC number, Vβ usages, and telomere lengths were observed in young donors during the 3-5 years course of donation whereas the middle-aged/old donors showed a rather striking stability in these measurements. This may reflect a more prominent role of thymic output in T cell regeneration in young than in middle-aged/old donors. Together, these findings provide an in vivo glimpse into the homeostasis of lymphocytes and monocytes in the blood at different ages, and support the notion that regeneration of lymphocytes and monocytes is robust throughout adult life up to the early 70s.Entities:
Keywords: CD31; T cell; TREC; leukapheresis; telomerase aging; telomere
Year: 2012 PMID: 22936935 PMCID: PMC3424600 DOI: 10.3389/fimmu.2012.00271
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Subject age, gender, and donation number.
| Aliasa | Gender | Age range | Donation#b |
|---|---|---|---|
| Y1 | M | 24-27 | 17 (7) |
| Y2 | M | 22-27 | 18 (4) |
| Y3 | F | 28-32 | 13 (7) |
| M1 | M | 50-54 | 22 (10) |
| M2 | M | 62-66 | 17 (10) |
| M3 | F | 70-73 | 13 (6) |
Vβ staining and change in CD4 and CD8T cells overtime.
| CD4 | CD8 | Time span (month) | |||||
|---|---|---|---|---|---|---|---|
| Donor | Percent[ | Increase | Decrease | Percent | Increase | Decrease | |
| Y1 | 49.7 | 47.5 | 14 | 46 | |||
| Y2 | 47.5 | 3, 13.2 | 5.3, 7.1, 1 | 42.4 | 3 | 5.3, 5.1, 7.2 | 59 |
| Y3 | 42.4 | 2, 17 | 38.8 | 8, 14, 21.3 | 26 | ||
| M1 | 38.5 | 1 | 34.5 | 1, 23 | 25 | ||
| M2 | 47.0 | 38.4 | 8 | 32 | |||
| M3 | 61.3 | 11 | 46.9 | 5.2 | 35 | ||
TCR Vβ repertoire usage was determined using a panel of 24 fluorochorme-conjugated antibodies against individual Vβ epitopes in PBMC along with antibodies against either CD4 or CD8. The sum of the percent of T cells staining positive for each Vβ genes are shown for each donor.
The SD of measurement error for each Vβ was calculated (see Results). The Vβ gene designation without * indicates the change ≥ 1 SD but < 2 SD, and with * indicates change ≥ 2 SD.